Macrophages are an important component of all prostate tumors; their presence is associated with cancer progression and clinical outcomes depending on their phenotype (either cytotoxic-M1 (CD68) or protumorigenic-M2 (CD163)). This evidence concerns the gene CD163 and cancer.